Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Antibody-Targeted Chemotherapy for the Treatment of Melanoma
Nevala, Wendy K. , Buhrow, Sarah A. , Knauer, Daniel J., Atanasova, Elena, Reid, Joel M. , Atanasova, Elena A, Markovic, Svetomir N.

Mayo Clinic

Cancer Research | April 29, 2016 | Volume: 76 | Issue: 13 | Pages: 3954-3964

10.1158/0008-5472.can-15-3131 | PMID 27197186 Get It

Abstract Antibody-directed chemotherapy (ADC) offers an advantage over conventional chemotherapy because it provides antibody-directed targeting, with resultant improvement in therapeutic efficacy and reduced toxicity. Despite extensive research, with notable exceptions, broad clinical application of ADC remains elusive; major hurdles include the instability of antibody–chemotherapy linkers and reduced tumor toxicity of the chemotherapy when bound to the antibody. To address these challenges, we have developed a platform technology that utilizes the nab-paclitaxel formulation of paclitaxel, Abraxane, in which hydrophobic paclitaxel is suspended in 130-nm albumin nanoparticles and thus made water-soluble. We have developed a method to noncovalently coat the Abraxane nanoparticle with recombinant mAbs (anti-VEGF, bevacizumab) and guide Abraxane delivery into tumors in a preclinical model of human A375 melanoma. Here, we define the binding characteristics of bevacizumab and Abraxane, demonstrate that the chemotherapy agent retains its cytotoxic effect, while the antibody maintains the ability to bind its ligand when the two are present in a single nanoparticle (AB160), and show that the nanoparticle yields improved antitumor efficacy in a preclinical human melanoma xenograft model. Further data suggest that numerous therapeutic monoclonal IgG1 antibodies may be utilized in this platform, which has implications for many solid and hematologic malignancies. Cancer Res; 76(13); 3954–64. ©2016 AACR.
The Effect of Message Framing on African American Women’s Intention to Participate in Health-Related Research
Balls‐Berry, Joyce E. , Parker, Monica W. , Halyard, Michele Y. , Albertie, Monica, Pinn, Vivian W. , Breitkopf, Carmen Radecki , Hayes, Sharonne, Halyard, Michele, Enders, Felicity , Radecki Breitkopf, Carmen, Hayes, Sharonne N. , Balls-Berry, Joyce Joy E

Mayo Clinic

Journal of Health Communication | April 14, 2016 | Volume: 21 | Issue: 5 | Pages: 527-533

10.1080/10810730.2015.1103333 | PMID 27077665 Get It

Prevalence of Submandibular Gland Synucleinopathy in Parkinson’s Disease, Dementia with Lewy Bodies and other Lewy Body Disorders
Beach, Thomas G. , Sue, Lucia I., Walker, Douglas G. , Dugger, Brittany N. , Shill, Holly A. , Driver‐Dunckley, Erika , Caviness, John N., Intorcia, Anthony J., Filon, Jessica, Scott, Sarah, Garcia, Angelica, Hoffman, Brittany, Belden, Christine M. , Davis, Kathryn, Driver-Dunckley, Erika, Adler, Charles H. , Serrano, Geidy E. , Sabbagh, Marwan Noel , Dugger, Brittany N

Mayo Clinic

Journal of Parkinson’s Disease | April 6, 2016 | Volume: 6 | Issue: 1 | Pages: 153-163

10.3233/jpd-150680 | PMID 26756744 Get It

Background: Clinical misdiagnosis, particularly at early disease stages, is a roadblock to finding new therapies for Lewy body disorders. Biopsy of a peripheral site might provide improved diagnostic accuracy. Previously, we reported, from both autopsy and needle biopsy, a high prevalence of submandibular gland synucleinopathy in Parkinson’s disease (PD). Here, we report on an extension of these studies to subjects with dementia with Lewy bodies (DLB) and other Lewy body disorders in 228 autopsied subjects from the Arizona Study of Aging and Neurodegenerative Disorders. Objective: To provide an estimate of the prevalence of histological synucleinopathy in the submandibular glands of subjects with PD and other Lewy body disorders. Methods: Submandibular gland sections from autopsied subjects were stained with an immunohistochemical method for α-synuclein phosphorylated at serine 129. Included were 146 cases with CNS Lewy-type synucleinopathy (LTS), composed of 46 PD, 28 DLB, 14 incidental Lewy body disease (ILBD), 33 Alzheimer’s disease with Lewy bodies (ADLB) and 2 with progressive supranuclear palsy and Lewy bodies (PSPLB). Control subjects included 79 normal elderly, 15 AD, 12 PSP, 2 conticobasal degeneration (CBD) and 2 multiple system atrophy (MSA). Results: Submandibular gland LTS was found in 42/47 (89%) of the PD subjects, 20/28 (71%) DLB, 4/33 (12%) ADLB and 1/9 (11%) ILBD subjects but none of the 110 control subjects. Conclusions: These results provide support for further clinical trials of in vivo submandibular gland diagnostic biopsy for PD and DLB. An accurate peripheral biopsy diagnosis would assist subject selection for clinical trials and could also be used to verify other biomarkers.
Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples
Brachtel, Elena F. , Operaña, Theresa N., Sullivan, Peggy , Kerr, Sarah E. , Cherkis, Karen, Schroeder, Brock E. , Schnabel, Catherine A. , Dry, Sarah

Mayo Clinic

Oncotarget | March 29, 2016 | Volume: 7 | Issue: 19 | Pages: 27220-27231

10.18632/oncotarget.8449 | PMID 27034010 Get It

Blood lipids and prostate cancer: a Mendelian randomization analysis
Bonilla, Carolina , Holly, Jeff M.P. , Perks, Claire M. , Davies, Neil M , Haycock, Philip , Richards, J. Brent , Eeles, Rosalind A. , Easton, Doug , Olama, Ali Amin Al , Benlloch, Sara, MacInnis, Robert J. , Grönberg, Henrik , Haiman, Christopher A. , Schleutker, Johanna , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Pashayan, Nora , Stanford, Janet L. , Blot, William J. , Thibodeau, Stephen N. , Maier, Christiane, Kibel, Adam S. , Brenner, Hermann , Park, Jong, Kaneva, Radka , Batra, Jyotsna , Teixeira, Manuel R. , Micheal, Agnieszka, Pandha, Hardev , Smith, George Davey , Lewis, Sarah J. , Martin, Richard M. , Thibodeau, Stephen, Bull, Caroline J. , Yu, Oriana Hoi Yun , Kote‐Jarai, Zsofia , Muir, Kenneth , Giles, Graham G. , Wiklund, Fredrik E. , Khaw, Kay‐Tee , Cybulski, Cezary , Cannon‐Albright, Lisa , Teixeira, Manuel R , Eeles, Rosalind A , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Maclnnis, Robert , Haycock, Philip , Brenner, Hermann , Martin, Richard M , Batra, Jyotsna , Davey Smith, George

Mayo Clinic

Cancer Medicine | March 19, 2016 | Volume: 5 | Issue: 6 | Pages: 1125-1136

10.1002/cam4.695 | PMID 26992435 Get It

AbstractGenetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer cases and 22,133 controls from 22 studies within the international PRACTICAL consortium were analyzed. Allele scores based on single nucleotide polymorphisms (SNPs) previously reported to be uniquely associated with each of low‐density lipoprotein (LDL), high‐density lipoprotein (HDL), and triglyceride (TG) levels, were first validated in an independent dataset, and then entered into logistic regression models to estimate the presence (and direction) of any causal effect of each lipid trait on prostate cancer risk. There was weak evidence for an association between the LDL genetic score and cancer grade: the odds ratio (OR) per genetically instrumented standard deviation (SD) in LDL, comparing high‐ (≥7 Gleason score) versus low‐grade (<7 Gleason score) cancers was 1.50 (95% CI: 0.92, 2.46; P = 0.11). A genetically instrumented SD increase in TGs was weakly associated with stage: the OR for advanced versus localized cancer per unit increase in genetic risk score was 1.68 (95% CI: 0.95, 3.00; P = 0.08). The rs12916‐T variant in 3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR) was inversely associated with prostate cancer (OR: 0.97; 95% CI: 0.94, 1.00; P = 0.03). In conclusion, circulating lipids, instrumented by our genetic risk scores, did not appear to alter prostate cancer risk. We found weak evidence that higher LDL and TG levels increase aggressive prostate cancer risk, and that a variant in HMGCR (that mimics the LDL lowering effect of statin drugs) reduces risk. However, inferences are limited by sample size and evidence of pleiotropy.
Improvement in Functioning and Psychological Distress in Adolescents With Postural Orthostatic Tachycardia Syndrome Following Interdisciplinary Treatment
Bruce, Barbara K. , Harrison, Tracy E. , Bee, Susan, Luedtke, Connie A. , Porter, Co-burn J., Hayes, Sarah , Allman, Daniel A., Ale, Chelsea M. , Weiss, Karen E. , Bee, Susan M, Fischer, Philip R. , Hayes, Sarah E

Mayo Clinic

Clinical Pediatrics | March 16, 2016 | Volume: 55 | Issue: 14 | Pages: 1300-1304

10.1177/0009922816638663 | PMID 26983448 Get It

Significant functional impairment and psychological distress have been observed in adolescent patients with postural orthostatic tachycardia syndrome (POTS). Interdisciplinary rehabilitation programs have been shown to be beneficial in the treatment of chronic pain in adults and adolescents. Only preliminary data have examined interdisciplinary rehabilitation efforts in patients with POTS. This study evaluated the impact of an interdisciplinary rehabilitation program on the functional impairment and psychological distress in 33 adolescents diagnosed with POTS. Patients included in the study were adolescents ages 11 to 18 diagnosed with POTS. Measures completed at admission and discharge from the program included the Functional Disability Index, Center for Epidemiological Studies–Depression–Child scale, and the Pain Catastrophizing Scale for Children. After participation in the 3-week program, adolescents with POTS demonstrated a significant increase in overall functional ability and significant reductions in depression and catastrophizing.
False Negative Cell-Free DNA Screening Result in a Newborn with Trisomy 13
Cao, Yang , Hoppman, Nicole L., Kerr, Sarah E. , Sattler, Christopher A., Borowski, Kristi, Wick, Myra , Highsmith, W. Edward, Borowski, Kristi S, Wick, Myra J, Aypar, Umut

Mayo Clinic

Case Reports in Genetics | February 22, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-5

10.1155/2016/7397405 | PMID 26998368 Get It

Background.Noninvasive prenatal screening (NIPS) is revolutionizing prenatal screening as a result of its increased sensitivity, specificity. NIPS analyzes cell-free fetal DNA (cffDNA) circulating in maternal plasma to detect fetal chromosome abnormalities. However, cffDNA originates from apoptotic placental trophoblast; therefore cffDNA is not always representative of the fetus. Although the published data for NIPS testing states that the current technique ensures high sensitivity and specificity for aneuploidy detection, false positives are possible due to isolated placental mosaicism, vanishing twin or cotwin demise, and maternal chromosome abnormalities or malignancy.Results.We report a case of false negative cell-free DNA (cfDNA) screening due to fetoplacental mosaicism. An infant male with negative cfDNA screening result was born with multiple congenital abnormalities. Postnatal chromosome and FISH studies on a blood specimen revealed trisomy 13 in 20/20 metaphases and 100% interphase nuclei, respectively. FISH analysis on tissues collected after delivery revealed extraembryonic mosaicism.Conclusions.Extraembryonic tissue mosaicism is likely responsible for the false negative cfDNA screening result. This case illustrates that a negative result does not rule out the possibility of a fetus affected with a trisomy, as cffDNA is derived from the placenta and therefore may not accurately represent the fetal genetic information.
Assessment of low-dose i.v. ketamine infusions for adjunctive analgesia
Kator, Sarah , Correll, Darin , Levinson, Radmila, Noronha, Genevieve N., Adams, Christopher , Ou, Judy Y.

Mayo Clinic

American Journal of Health-System Pharmacy | February 19, 2016 | Volume: 73 | Issue: 5_Supplement_1 | Pages: S22-S29

10.2146/ajhp150367 | PMID 26896522 Get It

Screening History Among Women with Invasive Cervical Cancer in an Academic Medical Center: Will We Miss Cancers Following Updated Guidelines?
Nitschmann, Caroline C., May, Taymaa , Mirković, Jelena , Nitschmann, Caroline, Feldman, Sarah

Mayo Clinic

Journal of Women's Health | February 9, 2016 | Volume: 25 | Issue: 8 | Pages: 826-831

10.1089/jwh.2015.5394 | PMID 26859535 Get It

The Method for Performance Measurement Matters: Diabetes Care Quality as Measured by Administrative Claims and Institutional Registry
Tulledge‐Scheitel, Sidna M. , Naessens, James M. , Glasgow, Amy E. , Stroebel, Robert J. , Crane, Sarah J. , Bunkers, Kari S., Shah, Nilay D. , Glasgow, Amy E. , Tulledge-Scheitel, Sidna M, McCoy, Rozalina G. , Glasgow, Amy E

Mayo Clinic

Health Services Research | February 5, 2016 | Volume: 51 | Issue: 6 | Pages: 2206-2220

10.1111/1475-6773.12453 | PMID 26846443 Get It

ObjectivesPerformance measurement is used by health care providers, payers, and patients. Historically accomplished using administrative data, registries are used increasingly to track and improve care. We assess how measured diabetes care quality differs when calculated using claims versus registry.Data Sources/Study SettingCross‐sectional analysis of administrative claims and electronic health records (EHRs) of patients in a multispecialty integrated health system in 2012 (n = 368,883).Study DesignWe calculated percent of patients attaining glycohemoglobin <8.0 percent, LDL cholesterol <100 mg/dL, blood pressure <140/90 mmHg, and nonsmoking (D4) in cohorts, identified by Medicare Accountable Care Organization/Minnesota Community Measures (ACO‐MNCM; claims‐based), Healthcare Effectiveness Data and Information Set (HEDIS; claims‐based), and registry (EHR‐based).Data Collection/Extraction MethodsClaims were linked to EHR to create a dataset of performance‐eligible patients.Principal FindingsACO‐MNCM, HEDIS, and registry identified 6,475, 6,989, and 6,425 measurement‐eligible patients. Half were common among the methods; discrepancies were due to attribution, age restriction, and encounter requirements. D4 attainment was lower in ACO‐MNCM (36.09 percent) and HEDIS (37.51 percent) compared to registry (43.74 percent) cohorts.ConclusionsRegistry‐ and claims‐based performance measurement methods identify different patients, resulting in different rates of quality metric attainment with implications for innovative population health management.